Search Bar & Filters
Found 27 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating the frequency of Neuronal Ceroid Lipofusinosis Type 2 CLN2 in children aged 2 to 6 years who have nonspecific neurological symptoms such as idiopathic seizures, speech disorders, and motor dysfunctions. This multicenter, non-drug screening study focuses on children without hypoxic ischemic encephalopathy, head trauma, or developmental brain anomalies, aiming to better understand the demographic and clinical features of those with possible CLN2 disease. Children first undergo assessments including recording demographic and medical history, seizure frequency, cognitive and language development evaluations, physical exams assessing muscle strength, gait, and coordination, as well as neurological evaluations using EEG and MRI scans. Those showing specific signs like speech disorder with seizures, movement problems, particular EEG responses, or MRI findings will have blood samples taken to measure Tripeptidyl Peptidase 1 enzyme levels. If enzyme activity is low, genetic testing is performed to investigate CLN2 disease. Participants are involved for up to one year during which various clinical, neurological, and imaging evaluations are done. Blood samples are collected for enzyme and genetic analyses. The main outcome measured is the frequency of CLN2 disease in this group. The study tracks each childs symptoms, neurological findings, and imaging results to better identify and understand CLN2 in children with these symptoms.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of several investigational long-acting antibody treatments, both alone and in combination, for adults with moderately to severely active ulcerative colitis UC. This Phase 2 platform study involves multiple centers and aims to improve treatment options for this condition by comparing different therapies. The study consists of two parts. Part A was an open-label phase assessing safety and early effectiveness of three monotherapies, which completed enrollment in April 2026. Part B is currently enrolling and is a randomized, placebo-controlled phase testing three monotherapies and three combination therapies against placebo. Participants will receive intravenous induction and subcutaneous maintenance treatments, with different dosing regimens evaluated over time. Participants will be monitored through regular assessments including endoscopy and histology to measure disease activity and response. The main outcomes include clinical remission and histologic improvement after 12 weeks, with longer-term remission assessed up to 48 weeks. Safety and efficacy data will be collected throughout, with treatment duration and follow-up determined by study protocol. The total study completion is expected by March 2028.
Actively Recruiting
Researchers are evaluating the effects of felzartamab in adults with Immunoglobulin A nephropathy IgAN, a kidney disease caused by the buildup of abnormal IgA antibodies in the kidneys. This buildup leads to inflammation and damage, resulting in protein in the urine proteinuria. The study aims to learn how felzartamab affects proteinuria and kidney function compared to a placebo, while also assessing the safety and how the drug is processed by the body. Participants will be randomly assigned to receive either intravenous IV infusions of felzartamab or a placebo that contains no active medicine. The treatment period lasts for 24 weeks, followed by an 80-week follow-up period. Some participants with lower kidney filtration rates will be included in specific cohorts receiving either felzartamab or placebo. Overall, participants will have 17 study visits during about 2 years in the trial. During the study, participants will undergo various assessments including urine protein measurement, kidney function tests using estimated glomerular filtration rate eGFR, and monitoring for immune responses and adverse events. Blood samples will be collected to measure drug levels and antibodies against felzartamab. Safety will be monitored through vital signs, laboratory tests, physical exams, and ECGs. Researchers will evaluate changes from baseline up to 36 weeks for proteinuria and up to 104 weeks for kidney function and safety outcomes.
Actively Recruiting
Researchers are investigating the effect of AI-assisted written patient information compared to standard verbal counseling on treatment adherence and patient-reported outcomes in adults with primary chronic anal fissure receiving initial medical or conservative treatment. This prospective, randomized controlled trial aims to see if AI-assisted written information can improve adherence to treatment by day 14. Secondary goals include evaluating pain, discomfort, quality of life, stool form, additional healthcare visits, need for interventional treatment, and patient satisfaction. Participants are randomly assigned in equal numbers to either receive standardized medical treatment plus AI-assisted written information or standardized medical treatment plus verbal counseling alone. Both groups follow the same medical treatment plan the only difference is how patient information is delivered. Assessments include face-to-face visits at baseline and week 6, plus telephone follow-ups on days 7 and 14. During the study, participants will be evaluated for treatment adherence at day 14, pain and discomfort levels at days 7, 14, and week 6, changes in patient global impression of change, quality of life scores, stool form, and healthcare utilization. The study involves multiple assessments through interviews and questionnaires, with monitoring continuing until week 6 to assess short-term outcomes. The total participation duration spans from initial evaluation through week 6 follow-up.
Actively Recruiting
Researchers are conducting a single-center, prospective, randomized controlled trial to compare two methods of delivering patient informationstandardized verbal counseling versus AI-assisted written informationin adults with symptomatic hemorrhoidal disease who are starting initial conservative or medical treatment. The primary goal is to see if AI-assisted written information can improve complete treatment adherence by day 14. Secondary goals include assessing changes in quality of life, symptom improvement, and healthcare visit frequency. Participants will be randomly assigned to one of two groups one receiving standardized verbal counseling along with medical treatment, and the other receiving investigator-validated AI-assisted written patient information containing the same content, plus medical treatment. Both groups receive the same standard medical treatment. Assessments occur at baseline, day 7, day 14, and day 28, focusing on treatment adherence and symptom changes. During the study, participants will be evaluated through symptom scores, quality-of-life questionnaires, and patient impressions of change. Researchers will measure pain, bleeding, swelling, itching, and soiling symptoms, as well as any unplanned healthcare visits. The study monitors participants up to 28 days with scheduled visits to assess treatment adherence and symptom progression comprehensively.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the underlying biological mechanisms of congenital sensorineural hearing loss in children. This observational case-control study compares levels of serum alpha-tectorin, interleukin-10 IL-10, and thiol-disulfide homeostasis among children with congenital hearing loss who use cochlear implants, those who use hearing aids, and healthy children with normal hearing. The goal is to better understand these mechanisms and identify potential biomarkers for diagnosis and prognosis. The study involves three groups of children under 18 years one with cochlear implants, one using hearing aids without implants, and a healthy control group. Each participant provides a single blood sample of about 5 mL. The blood is analyzed for serum alpha-tectorin, IL-10, and thiol-disulfide homeostasis parameters using enzyme-linked immunosorbent assay ELISA and spectrophotometric methods. The study collects clinical data, including birth history, device use, and hearing loss degree, to analyze correlations with biomarker levels. Participants undergo audiological testing before enrollment to confirm hearing status. Researchers collect demographic and clinical information and perform blood sample analysis at a single timepoint. The primary outcomes are the serum levels of alpha-tectorin, IL-10, and thiol-disulfide balance. Secondary outcomes include how these biomarkers relate to hearing loss severity. The overall participation involves one blood draw and clinical data collection during the study period ending in April 2027.
Actively Recruiting
Observing Outcomes and Patient Satisfaction After Laser Treatment for Internal Hemorrhoids in Adults
This observational study focuses on adults with symptomatic internal hemorrhoidal disease who are scheduled to undergo laser hemorrhoidoplasty. It aims to evaluate clinical outcomes including postoperative pain, complications, and patient satisfaction. The study also explores how hemorrhoid stage, main symptoms, and surgical details relate to recovery and overall results. The research is conducted at the General Surgery Clinic of Sanliurfa Education and Research Hospital. Participants will receive laser hemorrhoidoplasty, a minimally invasive procedure that uses laser energy to coagulate and shrink hemorrhoidal tissue without cutting. The study collects data during routine clinical care without adding any extra treatments. Surgical details such as laser wavelength and energy used, number of treated hemorrhoids, and any additional procedures will be recorded. Participants will be followed through their normal recovery process with assessments including pain scores at 6 hours, 24 hours, and 1 week after surgery. Researchers will track analgesic use, hospital stay length, time to resume daily activities, and any complications occurring within 30 days. Patient satisfaction and symptom recurrence will be evaluated up to 3 and 6 months after surgery. The study plans to clarify laser hemorrhoidoplastys clinical role and help guide patient selection.
Actively Recruiting
Researchers are comparing two types of nerve blocks used for pain control after inguinal hernia surgery the anterior iliac block and the ilioinguinaliliohypogastric block. The study aims to see which technique provides longer-lasting pain relief and better patient satisfaction. This comparison is important because effective pain management can improve comfort and reduce the need for opioid medications after surgery. Participants will receive either the anterior iliac block or the ilioinguinaliliohypogastric block after their hernia surgery. These nerve blocks are given to help manage pain at the surgical site. The study is randomized and double-blinded, meaning neither the patients nor the researchers know which block is being given to ensure unbiased results. During the study, pain levels will be measured using a Numeric Rating Scale NRS at multiple times after surgery 0, 1, 3, 6, 12, and 24 hours. Researchers will also assess patient satisfaction and track how much additional pain medication is needed. The study plans to start in April 2026 and follow participants until September 2026, focusing on safety and effectiveness of these pain relief methods.
Actively Recruiting
Researchers are evaluating the diagnostic accuracy of computed tomography CT reporting and the Appendicitis Inflammatory Response AIR score in adults suspected of having acute appendicitis who undergo appendectomy. The study aims to measure how often appendectomies are performed unnecessarily, based on final pathology results. It also examines how well the AIR score, CT findings, and surgical severity grading agree with pathology, and explores these diagnostics across different patient groups. This prospective observational study includes adults 18 years and older who visit the emergency department with suspected appendicitis, receive a CT scan showing signs of appendicitis, and then have an appendectomy. No extra treatments or interventions apart from standard care are performed. Clinical, demographic, and diagnostic data including laboratory results, CT reports, and surgical findings are collected and analyzed. Participants will have their clinical data recorded, including symptom details, lab tests, and imaging results. Researchers will compare CT reports, AIR scores, and surgical grades to final pathology findings within 30 days after surgery. The main measurement is the rate of negative appendectomies. Data is collected confidentially, with no study procedures beyond routine care, and the study is expected to end by January 2027.
1-10 of 27
1